Active Ingredient History
Dacomitinib is an oral, once-daily, pan-HER inhibitor. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomtinib is being evaluated in phase 3 clinical trials against nonsmall-cell lung cancer. Direct comparison with erlotinib did not show superiority of dacomtinib, but subgroup analysis have demonstrated that subgroup with exon 19 deletion had favorable outcomes with dacomitinib. In addition to nonsmall-cell lung cancer dacomtinib is being evaluated against esophagus, head and neck and other neoplasms. Due to its ability to pass through blood-brain barrier, dacomitinib can be used to treat brain tumors. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Non-Small-Cell Lung (approved 2018)
Adenocarcinoma (Phase 1)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Large Cell (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Squamous Cell (Phase 2)
Colorectal Neoplasms (Phase 1/Phase 2)
Esophageal Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Liver Diseases (Phase 1)
Lung Neoplasms (Phase 3)
Mouth Neoplasms (Phase 1/Phase 2)
Mutation (Early Phase 1)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Penile Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 4)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
